StockData
Dare Bioscience, Inc. logo

Dare Bioscience, Inc. (DARE) stock

DARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$0.43−0.16 (-26.57%)

Close on Nov 17, 2026Market cap $6.56MP/E –Yield –

Earnings

Dare Bioscience's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 12, 2026
Q3 FY2026 · estimated, after the close
Revenue, Q2 FY2026
$200.00K
– on a year earlier
EPS, Q2 FY2026
-$0.20
-$0.45 a year earlier
Latest guidance
Issued
Mar 28, 2024 · 1 item

Quarterly results

Revenue and earnings per share from each of Dare Bioscience's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 12, 2026Expected––––
Q2 FY2026ended Jun 30, 2026Aug 13, 2026after the close$200.00K–-$0.20Release
Q1 FY2026ended Mar 31, 2026May 14, 2026after the close$152.46K–-$0.20Release
Q4 FY2025ended Dec 31, 2025Mar 26, 2026after the close–––Release
Q3 FY2025ended Sep 30, 2025Nov 13, 2025after the close$2.26K-94.6%-$0.28Release
Q2 FY2025ended Jun 30, 2025Aug 14, 2025after the close-$21.17K-194.4%-$0.45Release
Q1 FY2025ended Mar 31, 2025May 13, 2025after the close–––Release
Q4 FY2024ended Dec 31, 2024Mar 31, 2025after the close–––Release
Q3 FY2024ended Sep 30, 2024Nov 14, 2024after the close$41.69K-95.8%-$0.55Release
Q2 FY2024ended Jun 30, 2024Aug 12, 2024after the close$22.44K–$1.52Release
Q1 FY2024ended Mar 31, 2024May 14, 2024before the open$9.30K–-$0.07Release
Q4 FY2023ended Dec 31, 2023Mar 28, 2024before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period Dare Bioscience guided for has been reported

Guidance history

Every forecast Dare Bioscience put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Mar 28, 2024G&A expensesFY2024$10.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Dare Bioscience filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Update
  4. News
  5. Results
  6. Update
  7. Update
  8. Update
  9. Results
  10. Update
  11. Results
  12. Update
  13. Update
  14. Update
  15. Results

See a number that looks wrong?